A Study to Evaluate the Safety and Efficacy of Ex Vivo Expanded Autologous Immune Killer Cells (IKC) in Stage IV Non-small Cell Lung Cancer (NSCLC) in Patients Who Failed Chemotherapy or Target Therapy

Exclusion Criteria

• •1. Patients with history of cardiovascular disease, including uncontrolled hypertension, congestive heart failure, myocardial infarction, angina pectoris, coronary artery disease, uncontrolled arrhythmia , previous history of encephalopathy within the past six months of screening period
• •2. Patients with HIV, HTLV or active tuberculosis
• •3. Women who are pregnant or breast-feeding
• •4. Patients with drug or other substance abuse
• •5. Patients with any other major disease, serious organ failure or patients unfit for participating in the trial (by the investigator's judgment)